A report by the National Advisory Committee on Immunization (NACI) warns against the use of the Moderna vaccine for boys and men between the ages of 12 and 29 due to the risk of heart inflammation. 

In Canada, over four million people have already received a shot of the Moderna vaccine.

As first revealed by Blacklock’s Reporter, NACI stated in an Updated Recommendation that the Pfizer-BioNTech vaccine is preferred over the Moderna shot due to data on myocarditis/pericarditis coming out of countries like Israel.

The reported rates of myocarditis among males aged 18 to 29 after the second vaccine dose were 15.9 per 100,000 for the Moderna vaccine and 2.6 per 100,000 for the Pfizer,” the NACI wrote. 

This amounts to a risk of myocarditis six times higher for Moderna. The report also states that “(i)ndividuals aged 12 to 29 years who have already received the Moderna 100mcg vaccine do not need to be concerned, as the risk of myocarditis/pericarditis with this vaccine is rare and events usually occur within a week following vaccination.”

According to the Public Health Agency (PHAC), there have been 1,376 reported cases of myocarditis, most often in 27-year-old males. 

“For individuals aged 12 to 29 receiving a COVID-19 vaccine primary series the use of Pfizer-BioNtech is preferred to Moderna to start or continue.” 

NACI also stated that the affected group should wait eight weeks between Pfizer doses to lower the risk of cardiac inflammation. 

“A longer interval between doses is associated with higher vaccine effectiveness and potentially lowers risk of myocarditis,” the Committee wrote. 

They added that the risk of recurrence of myocarditis following additional (third and more) doses of COVID-19 vaccines was unknown. “Very few cases of revaccination in these individuals have been described in published studies” their report read.

On recovery rates, the Committee cited US data that shows that those who did experience heart inflammation recovered in 91% of cases after three months. 

To date, PHAC has reported 27,747 “adverse events” of Canada’s 30.2 million COVID-19 vaccinations, 6,443 of which were considered to be serious.